|
Delayed
Nasdaq
05:26:22 31/10/26 am AEDT
|
5-day change | 1st Jan Change | ||
| 4.615 USD | +4.89% |
|
-12.43% | -63.90% |
| 07/08 | Cytosorbents Corporation, Q2 2026 Earnings Call, Aug 06, 2026 | |
| 07/08 | Cytosorbents Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 | CI |
Company Valuation: Cytosorbents Corporation
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 182.2 | 67.64 | 57.95 | 49.76 | 40.14 | 13.86 | - | - |
| Change | - | -62.87% | -14.31% | -14.14% | -19.32% | -65.46% | - | - |
| Enterprise Value (EV) | 182.2 | 67.64 | 57.95 | 49.76 | 40.14 | 13.86 | 13.86 | 13.86 |
| Change | - | -62.87% | -14.31% | -14.14% | -19.32% | -65.46% | 0% | 0% |
| P/E | -7.35x | -2.07x | -1.73x | -2.39x | -4.92x | -1x | -4.89x | 7.33x |
| PBR | - | - | - | - | - | - | - | - |
| PEG | - | -0.1x | 0.1x | 0.1x | 0.1x | -0x | 0.1x | -0x |
| Capitalization / Revenue | 4.22x | 1.95x | 1.59x | 1.27x | 1.08x | 0.36x | 0.31x | 0.27x |
| EV / Revenue | 0x | 0x | 0x | 0x | 0x | 0.36x | 0.31x | 0.27x |
| EV / EBITDA | -0x | -0x | -0x | -0x | -0x | -1.81x | -17.7x | - |
| EV / EBIT | -0x | -0x | -0x | -0x | -0x | -1.44x | -11.4x | 6.07x |
| EV / FCF | - | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -11.4 | -15 | -12.8 | -7.6 | -2.6 | -4.4 | -0.9 | 0.6 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 43.17 | 34.69 | 36.35 | 39.2 | 37.06 | 38.88 | 44.16 | 51.6 |
| EBITDA 1 | -15.81 | -26.84 | -26.05 | -11.46 | -13.3 | -7.667 | -0.7823 | - |
| EBIT 1 | -22.74 | -31.52 | -31.21 | -16.79 | -14.24 | -9.639 | -1.219 | 2.284 |
| Net income 1 | -24.56 | -32.81 | -28.51 | -20.72 | -8.198 | -13.91 | -2.772 | 2.284 |
| Net Debt | - | - | - | - | - | - | - | - |
| Reference price 2 | 83.800 | 31.000 | 22.200 | 18.200 | 12.784 | 4.400 | 4.400 | 4.400 |
| Nbr of stocks (in thousands) | 2,174 | 2,182 | 2,611 | 2,734 | 3,140 | 3,151 | - | - |
| Announcement Date | 8/3/22 | 9/3/23 | 14/3/24 | 31/3/25 | 25/3/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1x | - | - | - | 13.86M | |
| 36.31x | 6.19x | 23.63x | 0.26% | 262B | |
| 37.68x | 7.13x | 22.33x | 0.61% | 167B | |
| 51.69x | 12.54x | 26.9x | -.--% | 156B | |
| 17.32x | 3.52x | 11.43x | -.--% | 61.87B | |
| 37.44x | 7.51x | 23.77x | -.--% | 54.44B | |
| 21x | 2.51x | 12.66x | 2.4% | 53.3B | |
| 35.3x | 6.99x | 23.72x | 0.57% | 51.07B | |
| 47.51x | 11.7x | 25.8x | -.--% | 50.25B | |
| 84.04x | 7.96x | 24.17x | -.--% | 47.17B | |
| Average | 36.73x | 7.34x | 21.60x | 0.43% | 90.26B | |
| Weighted average by Cap. | 40.14x | 7.58x | 22.63x | 0.36% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- CTSO Stock
- Valuation Cytosorbents Corporation
Select your edition
All financial news and data tailored to specific country editions
